Weight loss cure Mounjaro is India's new drug market king

Drug unseats the previous best-selling antibiotic Augmentin, which had sales of ₹80 crore

- jessica [e-mail]

Since its launch late in March 2025, Eli Lilly's blockbuster weight-loss drug Mounjaro's total sales have reached ₹333 crore.

(REUTERS)

Sales of Eli Lilly’s blockbuster weight-loss drug Mounjaro have soared in India, making it the top-selling brand in October, just six months after its launch in the world's most populous nation.

The drug registered sales of ₹100 crore in October, unseating the previous bestselling antibiotic Augmentin, which recorded sales of ₹80 crore during the month, according to data from intelligence platform Pharmarack on Friday. Since its launch late in March 2025, Mounjaro's total sales have reached ₹333 crore.

Augmentin, the London-headquartered GSK’s broad-range antibiotic, still retains its top position on a moving annual total (MAT) basis, with sales of ₹863 crore in 12 months to October 2025. MAT refers to total sales seen over the latest 12-month period.

This marks Eli Lilly's sharp capture of India’s nascent anti-obesity market, outpacing competitor Novo Nordisk. ‘The brand took the second spot in sales in September, Pharmarack data showed.